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U.S. SPEAKER
Sara Rosenbaumt
Thank you very much.
It is a pleasure to be here with you today. It is my job to set the current
context for the issue of cross-border pharmaceutical sales between the U.S.
and Canada and to offer perspective on implications for U.S. policy and law.
Jennifer will then describe the issues that are coming up for Canada.
I should start by noting that I am neither an FDA (Food and Drug Ad-
ministration) lawyer, nor a drug safety expert. I teach health law and policy
with an emphasis on health care financing and health service and delivery.
My research emphasis is on health care for the poor and the intersection of
health care and civil rights. At the same time, I have followed this issue with
great interest, since cross-border sales represent the convergence of drug
safety and drug affordability. Whenever I hear "affordability," my ears perk
up at the thought of some strategy that might make healthcare more afford-
able. So, when I received this speaking invitation, I viewed it as an opportu-
nity to take a more in-depth view of cross-border sales, with the fresh eye of
someone who has formed no particularly pre-conceived notions about the
topic.
With this background, I begin by taking a step back to consider America
as a society. As you know, we are a strange and unique place, particularly
when contrasted against Canada. Here in the U.S., we have a deep libertarian
t Sara Rosenbaum is the Harold and Jane Hirsh Professor of Health Law and Policy and
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instinct. We don't like to be burdened in any way in our choices about much
of anything. We like at least the illusion - if not always the reality - of un-
ending choices and freedoms, and we don't like the government telling us
what to do. This is as true in health care as in any other endeavor, where the
nation's deep cultural belief in market freedom is reflected in the extent to
which the law of markets is applied to health care goods and services.' It is
of course, this social and cultural belief in unregulated markets, along with
the constraints imposed by a highly decentralized (and increasingly frac-
tured) political system that has for so long prevented the nation from making
the type of basic commitment to some form of universal health coverage as
Canada and other "first world" nations have done. As a corollary, I would
also note that we also have an abiding penchant for offsetting our failure to
act as a nation with quick fixes and "feel good" market solutions - such as
the discount purchasing of health care - that give us the illusion that we have
somehow attended to our basic problem of a lack of a national health system.
Discount cross-border drug purchasing, in my view, is, in the end, simply
another example of this tendency to try to solve systemic problems of access
and affordability, with unworkable and potentially unsafe solutions that do
little for the individuals whose health care access really is on the line.
Often this tension between what I consider to be a misplaced concept of
consumerism, and a commitment to some level of national policy solidarity,
is shielded. We create programs such as Medicaid, community health centers,
Medicare, and state and local indigent care programs, to mitigate the strong-
est effects of the market. Every once in a while however, the tension bubbles
to the surface, which is the case with cross-border prescription drug sales, as
proponents of broader reform, desperate for illustrative examples of just how
nationally off-kilter we are, seize on the variable price of prescription drugs
and use the issue as a driving symbol of the consequences of our national
policy vacuum. Here, though, symbology has morphed into reality, as the
pressure for cross-border sales has become an end in and of itself.
What is most striking to me about this particular example of symbology's
morphing into actual reform advocacy, is its high stakes nature. It is one
thing to bring boosterism for unbridled consumerism to health insurance
coverage itself. For example, according to some advocates, the answer to the
nation's uninsured crisis is to further deregulate an already heavily deregu-
lated health insurance system, and promote the sale of "discount" insurance
products that offer minimal coverage in exchange for a cut-rate fee.2 The
See RAND ROSENBLATT, SYLVIA LAW, AND SARA ROSENBAUM, LAW AND THE AMERICAN
HEALTH CARE SYSTEM, Introduction (Foundation Press 2001); See also Sara Rosenbaum, The
Impact of U.S. Law on Medicine as a Profession, 289 J. AM. MED. ASS'N, 1546-1555, (2003).See generally, Health Issues: Health Insurance Issues, National Center for Policy Analy-
sis, http://www.ncpa.org/iss/hea/i_insurance.html (providing several approaches to examine
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risk of these models is, of course, that they leave modest income people sig-
nificantly under-insured when serious illness strikes, while producing very
high profits for insurance companies allowed to charge premiums that, while
lower, actually may be very high in relation to "medical losses" (i.e., the ac-
tual payout after all the fine-print exclusions are applied).
The deregulation of drugs as part of expanded cross-border sales strate-
gies actually seems to me to be even more dangerous, however. Here the
issue is not just truth in advertising and serious under-financing of necessary
care without any supporting evidence to suggest that peolle either use too
much care, or that the slash in coverage will reduce price. Drug deregula-
tion, even in the case of deregulation in relation to a country such as Canada,
whose own drug laws are strong, inevitably raises safe'" concerns. In truth,
deregulation of drug sales is an approach that can proceed only with so many
cautions, caveats, and limitations, that in a more systemic context, the strat-
egy means little.
Even in a country that prizes open markets, we always have taken a dif-
ferent approach to drug sales. Pharmaceutical sales have been regulated for
decades under U.S. laws, and they have stood out as a notable exception to
America's penchant for totally open markets (compare the ability to buy
health care from any doctor who happens to hold a license regardless of field
of competence or effectiveness of care).
U.S. law related to prescription drugs regulates U.S. manufacturing and
sale, and to a significant degree, foreign manufacturing and sale.4 We do buy
drugs from abroad, from regulated manufacturers and plants. Of course, there
has always been, as there will be with any society, some leakage, meaning
there have always been people who bring in prescription drugs from other
countries whose markets may be significantly unregulated.5 The FDA has the
authority to stop these drugs at the border, even though historically it has
used its considerable agency discretion to take a relatively "hands-off' ap-
proach to individual transport cases.6 In these isolated cases of individual
the sale of "discount" insurance products); see also, Michael J. New, The Effect of State
Regulation on Health Insurance Premiums: A Preliminary Analysis 2 (2005), available at
http://www.heritage.org/Research/HealthCarelloader.cffm?url=/commonspot/security/getfile.cf
m&PagelD=84532.
3 See Gerard F. Anderson, Peter S. Hussey, Bianca K. Frogner, and Hugh R. Waters,
Health Spending in the United States and the Rest of the Industrialized World; Examining the
Impact of Waiting Lists and Litigation Reveals No Significant Effects on the U.S. Health
Spending Differential, HEALTH AFFAIRS, July-Aug. 2005, at 903-14.
4 Federal Food, Drug, and Cosmetic Act, 21 U.S.C.S. § 360 (2005).
5 See, e.g. Carlye Adler, Which Is Safe To Take? Counterfeit Drugs Are Big Business in
Asia. Here's What You Need to Know to Ensure You're Not Buying Bad Medicine, TIME
INTERNATIONAL, June 7, 2004, at 40.
6 21 C.F.R. § 26.21 (1998); but see also A Prescription for Safety: The Need for H.R.
3880, the Internet Pharmacy Consumer Protection Act: Hearing Before the H. Comm. On
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conduct, the FDA essentially has adopted an "assumed risk" stance. This
careful approach to enforcement is no different from the conduct of public
agencies generally in their law enforcement roles, which may on occasion
elect not to aggressively pursue every case of high-risk conduct - selective
enforcement if you will - in the recognition of limited resources and a social
penchant against regulatory zealots.
7
Although selective enforcement in individual cases can be, and perhaps
might be, considered typical public conduct, at the same time, Americans
should be concerned about broad and widespread enforcement of large scale
commercial conduct that carries far broader social and health risks. In this
context, we expect the FDA to protect us, and we should be rightfully con-
cerned about the general lack of resources accorded to the FDA to carry out
both pre and postmarketing responsibilities. The notion that we would en-
courage large commercial cross-border sales in the face of an agency that is
so ill-equipped to police such sales - even when the sales ostensibly come
from a nation whose prescription drug supply we consider safe - is contrary
to basic principles of public health protection in my view.
The question is how did we come to the situation in which we find our-
selves today? Clearly the events of 2003, in particular, the enactment of the
Medicare Modernization Act (MMA), which among other reforms, added
outpatient prescription drug coverage to Medicare,8 caused the nation to fo-
cus hard on the financial and political considerations that underlie the enact-
ment of laws aimed at dealing at a systemic level with the lack of sufficient
health insurance coverage. During the debate, which lasted for years - and
under numerous previous Administrations prior to passage of the MMA 9 -
Gov't Reform, 109 th Cong. 7-8 (2004) (statement of John M. Rector, Senior Vice Present of
Government Affairs and General Counsel for the National Community Pharmacists Associa-
tion, citing Christopher Rowland, FDA Drug Scrutiny Rapped as Uneven, THE BOSTON
GLOBE, Sept. 16, 2003 at Al).
7 This general penchant for selective regulation of wholly personal conduct is also recog-
nition of the privacy rights that Americans prize. Over the past half century, the United States
Supreme Court has dealt extensively with this clash between personal privacy and public
regulation in the context of abortion (Roe v. Wade, 410 U.S. 959 (1973)), end of life treatment
(Cruzan v. Missouri, 497 U.S. 261 (1990)), assisted suicide (Washington v. Glucksberg, 521
U.S. 702 (1997)), and medical marijuana (Ashcroft v. Raich, 542 U.S. 936 (2004)).
8 Medicare Prescription Drug, Improvement and Modernization Act of 2003, PUB. L. No.
108-173, 117 Stat. 2066 (codified in scattered sections of 42 U.S.C.).
9 Medicare's failure to provide ouipatient prescription drugs has been a notable program
shortcoming since its enactment. Outpatient prescription coverage originally was added to
Medicare under the Reagan Administration in 1988 and subsequently repealed in 1989. Medi-
care Catastrophic Coverage Act of 1988, Pub. L. No. 100-360; Medicare Catastrophic Cover-
age Repeal Act of 1989, Pub. L. No. 101-234. Proposals to add prescription drug coverage
were revived during the Clinton Administration beginning in 1998. See, e.g., Dr. Robert E.
Moffit, Heritage Foundation Lecture No. 647: A High Price Prescription: Clinton's Medicare
Drug Proposal (Nov. 3, 1999), http://www.heritage.org/Research/HealthCare/HL 6 4 7.cfm.
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much attention came to be paid to the price of prescription drugs, as well as
to widespread evidence of their availability abroad at a lower price. While
numerous factors related to the overall drug market underlie these pricing
differences (such as differences in approaches to government control of pric-
ing, the use of patent law, the presence of a generic market, and other consid-
erations), nonetheless policymakers became increasingly exposed to the sim-
ple issue of pricing differentials. In the end, this fact alone was bound to
carry implications.
Also a consideration is the form of the MMA. The MMA model is that of
a defined contribution arrangement. The Government essentially subsidizes
enrollment by beneficiaries into private, somewhat regulated, prescription
drug plans. This market model of course brings attention generally to the
market for prescription drugs and causes policy makers to focus on consum-
erism in health care generally.
A third issue as well is the somewhat "in-your-face" nature of the pre-
scription drug law itself. The rationale for the language is completely obvi-
ous: As a defined contribution statute, the law is structured to allow the
"magic of the market" to flourish. The government's role is to define the
product that will be purchased and to create the conditions under which a
market can flourish; it is not to administer prices. Not content to be clear
about what the government should do, the drafters also decided to stick their
legal fingers in the eyes of the law's opponents with a now famous "non-
interference" clause designed to underscore the lack of authority to adminis-
ter prices.10 This clause was sure to add fuel to the battle over the extent to
which government was prepared (as so alleged) to let manufacturers run
amok. Rather than stress the government's powers to design the product and
create the conditions for efficient buying and selling, the law appeared to
pander to the pharmaceutical industry, buying just the type of political
"blowback" that one sees in the issue of cross-border sales.
This non-interference clause helped spur the uproar over the legislation's
structure and cost, and inevitably set the political stage for the fight over "re-
importation" and cross-border sales, both of which were perceived as addi-
tional market strategies for driving costs downward, concerns over the safety
issues to the contrary.
The uproar has continued, with the Department of Health and Human
Services mandated to hold hearings and prepare a report to Congress.1" That
10 See Jill Wechsler, The Main Event Begins: Thorny Issues Are Already Emerging About
Medicare Rx; Washington Report, Vol. 25 No. 3 PHARMACEUTICAL EXECUTIVE 42, Mar. 1,
2005; see also Sens. Olympia Snowe (R-Maine) and Ron Wyden (D-Oregon), Press Release,
Sens. Snowe - Wyden Amendment Would Strengthen Medicare Drug Benefit, Nov. 4, 2005.
11 HHS Task Force on Drug Importation, Report on Prescription Drug Importation (Dec.
2004), http://www.hhs.gov/importtaskforce/Report1220.pdf.
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report, submitted to Congress at the end of 2004, makes a series of findings
regarding satisfaction of the legal standards governing re-importation, and
further concludes that the standards have not been met. Indeed, the report
identified a number of risks flowing from importation, even from a nation
such as Canada, whose regulatory framework and standards toward pharma-
ceuticals are similar to our own. Beyond the safety concerns, the report
found, not surprisingly, that in the cold light of day, the anticipated savings
from cross-border sales actually would be quite low. 12 While the hearings
certainly yielded isolated examples of deep discounts achievable through
cross-border sales, these isolated examples must be compared against the
generic market in the U.S., as well as the cost of setting up appropriate safe-
guards.
One of the issues that was not pointed out in the 2004 report, but which I
would add to the list of concerns is that, were evidence of safety concerns to
arise from cross-border discounting, such evidence might deter more affluent
group purchasers, but not group buyers whose coffers are perpetually inade-
quate in comparison to need: State Medicaid agencies, public hospitals and
health systems, community health centers, and other programs targeted to
low income and highly medically vulnerable population. My deepest con-
cerns about these systems have to do with the fact that ultimately they would
come to serve those who can least afford health care, thereby leading to a
further diminution if public willingness to invest in elaborate safety proce-
dures and aggressive inspections. One of the great things about public health
issues such as drug safety, is that the legal structure that governs the system
is seen as binding all of us, not simply those who can afford the best health
care. Allowing a discounting system without adequate safeguards ultimately
would fall out of favor in my view, with the residual system most heavily
used by those programs with the most urgent need to find the lowest cost
source of health care.
And with that, I think I will turn to Jennifer.
"2 Id. at XII-XIII.
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